Torrent Pharmaceuticals Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Torrent Pharmaceuticals Ltd. authored by IDBI Capital and published by - Trendlyne research reports.
Item: Torrent Pharmaceuticals Ltd.
Rating: 4
Author: IDBI Capital

Keep track of all breaking news and updates on Torrent Pharmaceuticals Ltd. from all sources in a single place.

Load latest

Torrent Pharmaceuticals Ltd.

25 Jul 2019

3255.20

-2.01%

AGM

Torrent Pharmaceuticals Ltd - 500420 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

BSE India

Torrent Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here

Torrent Pharmaceuticals Ltd.

25 Jul 2019

3255.20

-2.01%

Torrent Pharmaceuticals: Q1FY20 Result Review

Accumulate: Torrent Pharmaceuticals Ltd.

Target

IDBI Capital

Torrent Pharma (Torrent) reported an all-round improvement in Q1FY20 and exceed our earnings estimate by 11% (mainly due to 130bps beat on EBIDTA margin). It reported 8%/13.4%/32.5% YoY growth in revenue/EBIDTA/Adj. PAT to Rs20.22bn/Rs5.41/Rs2.16bn, respectively. Q1 revenue growth was added by resumption in supplies of Losaratan in US and improved pricing in India business. The management gave a cautious outlook for US, as new product approvals in US from its Dahej and Indrad facility will be withheld until the resolution of USFDA's Form -483s. We expect the overall performance to remain moderate in FY20 due to weaker traction in US, but will see a recovery in FY21 on normalization of...

Torrent Pharmaceuticals Ltd. is trading above its 100 day SMA of 3226.2

Torrent Pharmaceuticals Ltd.

24 Jul 2019

3255.20

-2.01%

Torrent Pharma sees best day in over 11 months as Q1 profit beats estimates

Business Line

Shares of Torrent Pharmaceuticals Ltd rose as much as 6.2 per cent to Rs 1,559, posting their biggest intra-day per cent gain since August 3, 2018.Jun

Torrent Pharmaceuticals Ltd. is trading above its 100 day SMA of 3226.2

Torrent Pharma standalone Q3 net up 83%

Business Line | 24 Jul 2019 1 more

Torrent Pharmaceuticals Ltd.

24 Jul 2019

3255.20

-2.01%

Torrent Pharma (1QFY20): Visible slowdown in the US biz. Maintain NEUTRAL

Neutral: Torrent Pharmaceuticals Ltd.

Target

HDFC Securities

While we remain constructive of TRP's domestic business owing to a strong presence in specialty chronic therapies, the slowdown in the US will limit revenue growth to low double digits (~12%) over FY19-21E. With the WL on Dahej, pending approvals in the US will get delayed, thus leaving margin expansion in check (+30bps to 26.2%). The mainstay domestic business will enable yearly FCF of Rs 13bn+ and net debt to drop by ~Rs 20bn over FY19-21E, aiding ~30% EPS CAGR over the period. With the update on Indrad expected soon, we remain cautious on the stock and would suggest entering post a favourable outcome. We maintain NEUTRAL on TRP following an in-line quarter. The domestic business enabled healthy growth in revenue and profitability. Yet, the slowdown in the US will continue for 2-3 quarters. We cut our estimates by ~5% owing to the WL for Dahej and await an update on Indrad. At 24x FY21E EPS, we arrive at a TP of Rs 1,615.

Torrent Pharmaceutic.. has an average target of 3522.40 from 6 brokers.

Torrent Pharmaceuticals Ltd.

24 Jul 2019

3255.20

-2.01%

Torrent Pharma: Results in line, OAI overhang

Hold: Torrent Pharmaceuticals Ltd.

Recommendation Target

Karvy

In Q1FY20, Torrent Pharma's revenues have increased by 8% YoY to Rs 20220 mn (our estimates Rs 202380 mn).

Torrent Pharmaceuticals Ltd. is trading below its 150 day SMA of 3256.0

Torrent Pharmaceuticals Ltd.

24 Jul 2019

3255.20

-2.01%

Torrent Pharmaceuticals

Buy: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

India growth steady; acquisitions to enhance coverage Domestic branded formulations including CRAMs constitute 48% of sales. The acquisition of Elder Pharma's branded portfolio has added new therapies like neutraceuticals, gynaecology and helped fill up portfolio gaps. The Unichem acquisition has added branded portfolio comprising some power brands besides achievement of long term synergy benefits. We...

Torrent Pharmaceutic.. has an average target of 3522.40 from 6 brokers.

Torrent Pharmaceuticals Ltd.

24 Jul 2019

3255.20

-2.01%

Torrent Pharma - 1QFY20 Result Update

Buy: Torrent Pharmaceuticals Ltd.

Target

Reliance Securities

Torrent Pharmaceutic.. has an average target of 3522.40 from 6 brokers.

Torrent Pharmaceuticals Ltd.

23 Jul 2019

3255.20

-2.01%

AGM

Torrent Pharmaceuticals Ltd - 500420 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

BSE India

46TH ANNUAL GENERAL MEETING HELD ON 23RD JULY, 2019 - Declaration of Results of e-voting and poll

pdf

Torrent Pharmaceuticals Ltd.

23 Jul 2019

3255.20

-2.01%

Company Update

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

The Board has at its meeting held today approved the appointment of Shri Jinesh Shah as an Additional Director on the Board of the Company till the next Annual General Meeting and also Whole-time Director, designated as Director (Operations) for a period of 5 years with effect from 01-Aug-19 subject to approval of the shareholders. He is not related to any other Director of the Company. Further, we would like to inform that Shri Shah is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

pdf

Torrent Pharmaceuticals Ltd.

23 Jul 2019

3255.20

-2.01%

Investor Presentation

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

The presentation on unaudited Consolidated Financial Results for the quarter ended 30th June, 2019 to be made to analysts is enclosed for your records.

pdf

Is Torrent Pharmaceuticals Ltd. worth buying?

145 Votes:

Buy 75.17%

Sell 15.86%

Hold 8.97%

RESEARCH REPORTS

Neutral SEE REPORTS >

pdf

Results Update SEE REPORTS >

pdf